News
http://www.exac.com
daily12007-11-26T15:37:37ZExactech Q1 Revenue Up 10% to $58.6 Million, Net Income $3.3 Million, Diluted EPS $0.25 http://www.exac.com/news/exactech-q1-revenue-up-10-to-58.6-million-net-income-3.3-million-diluted-eps-0.25 GAINESVILLE, Fla. – May 1, 2012 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $58.6 million for the first quarter of 2012, a 10% increase over $53.4 million in the first quarter of 2011. Net income was $3.3 million, or $0.25 per diluted share, compared to $3.0 million, or $0.22 per diluted share, in the same quarter a year ago.No publishermindy.underberger@exac.comPress Releases2012-05-01T20:45:44ZNews ItemExactech Schedules First Quarter 2012 Earnings Release and Conference Call http://www.exac.com/news/exactech-schedules-first-quarter-2012-earnings-release-and-conference-call GAINESVILLE, Fla. – April 17, 2012 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its first quarter 2012 financial results on Tuesday, May 1, 2012.No publishermindy.underberger@exac.comPress Releases2012-04-17T19:31:58ZNews ItemExactech Announces Expiration of Deferred Prosecution Agreement http://www.exac.com/news/exactech-announces-expiration-of-deferred-prosecution-agreement GAINESVILLE, Fla. – March 15, 2012 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the Deferred Prosecution Agreement (DPA) entered into effective December 7, 2010 with the United States Attorney’s Office for the District of New Jersey (USAO) has expired.No publishermindy.underberger@exac.comPress Releases2012-03-15T16:30:45ZNews ItemExactech 2011 Revenue Up 8% to $205M; Net Income $8.8M, EPS $0.67; Q4 Net Income $1.8M, EPS $0.14 http://www.exac.com/news/exactech-2011-revenue-up-8-to-205m-net-income-8.8m-eps-0.67-q4-net-income-1.8m-eps-0.14 GAINESVILLE, Fla. – February 28, 2012 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, extremities, spine and biologic materials, announced today that revenue for 2011 increased 8% to $205.4 million from $190.5 million in 2010.No publishermindy.underberger@exac.comPress Releases2012-02-28T21:31:34ZNews ItemExactech Announces $100 Million Long Term Syndicated Credit Facility http://www.exac.com/news/exactech-announces-100-million-long-term-syndicated-credit-facility Feb. 27, 2012 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of
bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today
announced that it has entered into a $100 million Credit Agreement with a syndicate of banks led by
SunTrust Robinson Humphrey that includes BBVA Compass, HSBC, Synovus Bank and Hancock
Bank.No publishermindy.underberger@exac.comPress Releases2012-02-27T21:20:46ZNews ItemExactech Announces Product Lineup for Exhibit at American Academy of Orthopaedic Surgeons Meeting. Management to Present at Investor Conference http://www.exac.com/news/exactech-announces-product-lineup-for-exhibit-at-american-academy-of-orthopaedic-surgeons-meeting.-management-to-present-at-investor-conference-1 GAINESVILLE, Fla. – February 6, 2012 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced its schedule of upcoming investor events.
Exactech President David Petty will present at the 2012 Canaccord Genuity 7th Annual Musculoskeletal Conference on Tuesday, February 7, 2012 in San Francisco, California at 10:40 a.m. Pacific Time. The investor conference includes companies in orthopaedics, biologics, regenerative medicine, dental, ENT, imaging, robotic surgery and tissue sculpting. Exactech’s presentation to investors will also be available via audio webcast at http://www.hawkassociates.com/profile/exac.cfm
No publishermindy.underberger@exac.comPress Releases2012-02-07T14:23:53ZNews ItemExactech Announces Preliminary 2011 Sales of $205.4 Million and 4th Quarter 2011 Sales of $53.1 Million http://www.exac.com/news/exactech-announces-preliminary-2011-sales-of-205.4-million-and-4th-quarter-2011-sales-of-53.1-million GAINESVILLE, Fla. – January 31, 2012 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it expects to report revenue for the fourth quarter of 2011 of $53.1 million, an increase of 2.5% compared to $51.8 million for the fourth quarter of 2010 which will result in full year unaudited revenues of $205.4 million, compared to $190.5 million for 2010, an 8% increase. For the full year 2011, U.S. sales increased 1% to $133.0 million and international sales increased 24% to $72.4 million. During the fourth quarter, U.S. sales decreased 2% to $34.0 million and international sales increased 11% during the quarter to $19.1 million.No publishermindy.underberger@exac.comPress Releases2012-01-31T21:24:41ZNews ItemExactech to Present to Investors at the 2012 Noble Financial Equity Conference on Jan 17 http://www.exac.com/news/exactech-to-present-to-investors-at-the-2012-noble-financial-equity-conference-on-jan-17 GAINESVILLE, Fla. – Jan. 9, 2012 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced that President David Petty and Chief Financial Officer Jody Phillips will present at the Eighth Annual Noble Financial Equity Conference in Hollywood, Florida on Tuesday, January 17th at 10:00 a.m. EST. No publishermindy.underberger@exac.comPress Releases2012-01-09T19:05:09ZNews Item